TY - JOUR
T1 - Improving the Techniques for Human Hepatocyte Transplantation
T2 - Report From a Consensus Meeting in London
AU - Puppi, Juliana
AU - Strom, Stephen C.
AU - Hughes, Robin D.
AU - Bansal, Sanjay
AU - Castell, Jose V.
AU - Dagher, Ibrahim
AU - Ellis, Ewa C. S.
AU - Nowak, Greg
AU - Ericzon, Bo-Goran
AU - Fox, Ira J.
AU - Jose Gomez-Lechon, M.
AU - Guha, Chandan
AU - Gupta, Sanjeev
AU - Mitry, Ragai R.
AU - Ohashi, Kazuo
AU - Ott, Michael
AU - Reid, Lola M.
AU - Roy-Chowdhury, Jayanta
AU - Sokal, Etienne
AU - Weber, Anne
AU - Dhawan, Anil
PY - 2012
Y1 - 2012
N2 - On September 6 and 7, 2009 a meeting was held in London to identify and discuss what are perceived to be current roadblocks to effective hepatocyte transplantation as it is currently practiced in the clinics and, where possible, to offer suggestions to overcome the blocks and improve the outcomes for this cellular therapy. Present were representatives of most of the active clinical hepatocyte transplant programs along with other scientists who have contributed substantial basic research to this field. Over the 2-day sessions based on the experience of the participants, numerous roadblocks or challenges were identified, including the source of cells for the transplants and problems with tracking cells following transplantation. Much of the discussion was focused on methods to improve engraftment and proliferation of donor cells posttransplantation. The group concluded that, for now, parenchymal hepatocytes isolated from donor livers remain the best cell source for transplantation. It was reported that investigations with other cell sources, including stem cells, were at the preclinical and early clinical stages. Numerous methods to modulate the immune reaction and vascular changes that accompany hepatocyte transplantation were proposed. It was agreed that, to obtain sufficient levels of repopulation of liver with donor cells in patients with metabolic liver disease, some form of liver preconditioning would likely be required to enhance the engraftment and/or proliferation of donor cells. It was reported that clinical protocols for preconditioning by hepatic irradiation, portal vein embolization, and surgical resection had been developed and that clinical studies using these protocols would be initiated in the near future. Participants concluded that sharing information between the groups, including standard information concerning the quality and function of the transplanted cells prior to transplantation, clinical information on outcomes, and standard preconditioning protocols, would help move the field forward and was encouraged.
AB - On September 6 and 7, 2009 a meeting was held in London to identify and discuss what are perceived to be current roadblocks to effective hepatocyte transplantation as it is currently practiced in the clinics and, where possible, to offer suggestions to overcome the blocks and improve the outcomes for this cellular therapy. Present were representatives of most of the active clinical hepatocyte transplant programs along with other scientists who have contributed substantial basic research to this field. Over the 2-day sessions based on the experience of the participants, numerous roadblocks or challenges were identified, including the source of cells for the transplants and problems with tracking cells following transplantation. Much of the discussion was focused on methods to improve engraftment and proliferation of donor cells posttransplantation. The group concluded that, for now, parenchymal hepatocytes isolated from donor livers remain the best cell source for transplantation. It was reported that investigations with other cell sources, including stem cells, were at the preclinical and early clinical stages. Numerous methods to modulate the immune reaction and vascular changes that accompany hepatocyte transplantation were proposed. It was agreed that, to obtain sufficient levels of repopulation of liver with donor cells in patients with metabolic liver disease, some form of liver preconditioning would likely be required to enhance the engraftment and/or proliferation of donor cells. It was reported that clinical protocols for preconditioning by hepatic irradiation, portal vein embolization, and surgical resection had been developed and that clinical studies using these protocols would be initiated in the near future. Participants concluded that sharing information between the groups, including standard information concerning the quality and function of the transplanted cells prior to transplantation, clinical information on outcomes, and standard preconditioning protocols, would help move the field forward and was encouraged.
KW - Hepatocyte transplantation
KW - Engraftment
KW - Radiation
KW - Stem cell
KW - Metabolic liver disease
KW - MESENCHYMAL STEM-CELLS
KW - VIVO GENE-THERAPY
KW - HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
KW - HEPATIC SINUSOIDAL ENDOTHELIUM
KW - PORTAL-VEIN EMBOLIZATION
KW - RAT-LIVER
KW - IN-VITRO
KW - ISLET TRANSPLANTATION
KW - PORCINE HEPATOCYTES
KW - NONHUMAN-PRIMATES
U2 - 10.3727/096368911X566208
DO - 10.3727/096368911X566208
M3 - Literature review
SN - 0963-6897
VL - 21
SP - 1
EP - 10
JO - Cell Transplantation
JF - Cell Transplantation
IS - 1
ER -